SCHEMBL3803695

SCHEMBL3803695

CCN(CC)CCNC(=O)CCc1c(C=C2C(=O)Nc3ccc(S(=O)(=O)N4CCc5ccccc54)cc32)[nH]c(C)c1C(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.64
AURKB Q96GD4 6/20 0.64
MET P08581 2/20 0.60
KDR P35968 9/20 0.48
PRKAA1 Q13131 9/20 0.48
PRKAA2 P54646 8/20 0.48
PDGFRB P09619 5/20 0.47
FGFR1 P11362 4/20 0.47
FLT3 P36888 4/20 0.46
EGFR P00533 3/20 0.46
PLK4 O00444 2/20 0.46
DCLK1 O15075 2/20 0.46
PDPK1 O15530 2/20 0.46
DAPK3 O43293 2/20 0.46
ROCK2 O75116 2/20 0.46
RPS6KA5 O75582 2/20 0.46
RPS6KA4 O75676 2/20 0.46
MAP4K4 O95819 2/20 0.46
CHEK2 O96017 2/20 0.46
NTRK1 P04629 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3803693 1.00 AURKA (0.64) AURKAAURKBMETKDRPRKAA1
SCHEMBL3797737 0.88 AURKA (0.72) AURKAAURKBMETKDRPRKAA1
SCHEMBL3797740 0.88 AURKA (0.72) AURKAAURKBMETKDRPRKAA1
SCHEMBL3793248 0.87 AURKA (0.82) AURKAAURKBMET
SCHEMBL3793253 0.87 AURKA (0.82) AURKAAURKBMET
SCHEMBL5414487 0.87 AURKB (0.63) AURKAAURKBMETKDRPRKAA1
SCHEMBL14595086 0.87 MET (0.69) AURKAAURKBMETKDRPRKAA1
SCHEMBL12847575 0.86 KDR (0.48) AURKAAURKBMETKDRPRKAA1
SCHEMBL3808724 0.85 MET (0.75) AURKAAURKBMETKDRPDGFRB
SCHEMBL3805989 0.85 MET (0.75) AURKAAURKBMETKDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US claimed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors CDK2, MAP3K19, MAP3K20 AURKA 96/4885AURKB 69/4885MET 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.